Skip to main content

Advertisement

Table 1 Clinical, demographic, parasitological and drug susceptibility data for all strains

From: Susceptibility testing of Leishmania spp. against amphotericin B and fluconazole using the Sensititre™ YeastOne™ YO9 platform

Strain Amphotericin B (μg/mL) Fluconazole (μg/mL) Isolate Origin New or Old World Origin Clinical Manifestation
L. amazonensis ATCC®50159™ 0.58 ± 0.22 ≥256 Brazil New World CL
L. chagasi ATCC®50133™ 0.33 ± 0.08 ≥256 Brazil New World VL
L. donovani ATCC®50212™ 0.25 ± 0.00 ≥256 India Old World VL
L. infantum ATCC®50134™ 0.22 ± 0.07 ≥256 Tunisia Old World VL
L. major ATCC®50122™ 0.44 ± 0.06 ≥256 Israel Old World CL
L. mexicana ATCC®50157™ 0.33 ± 0.08 ≥256 Belize New World CL
L. tropica ATCC®50129™ 0.25 ± 0.00 ≥256 Former USSR (Azerbaidjanskaya) Old World CL
L. V. braziliensis ATCC® 50135™ 0.25 ± 0.00 ≥256 Brazil New World CL or ML
L. V. guyanensis ATCC®50126™ 0.39 ± 0.09 ≥256 Brazil New World CL or ML
L. V. panamensis ATCC®50158™ 0.5 ± 0.00 ≥256 Panama New World CL or ML
Clinical L. infantum 1 0.12 ± 0.00 ≥256 Italy Old World VL
Clinical L. tropica 1 0.25 ± 0.00 ≥256 Afghanistan Old World CL
Clinical L. tropica 2 0.25 ± 0.00 ≥256 Afghanistan Old World CL
Clinical L. V. braziliensis 1 0.5 ± 0.00 ≥256 Peru New World CL
Clinical L. V. panamensis 1 0.12 ± 0.00 ≥256 Costa Rica New World CL
Clinical L. V. panamensis 2 0.16 ± 0.04 ≥256 Costa Rica New World CL
Clinical L. V. panamensis 3 0.12 ± 0.00 ≥256 Costa Rica New World CL
Clinical L. V. panamensis 4 0.67 ± 0.17 ≥256 Ecuador New World CL
Clinical L. V. panamensis 5 0.49 ± 0.08 ≥256 Costa Rica New World CL